Monthly Archives: August 2012

As American as Acid Reflux

By Ben Comer | Published: August 21, 2012
Over the counter drug advertising is less regulated than prescription drug marketing, and selling directly to consumers comes with the benefit of bypassing an expert middleman: your doctor. But companies should still promote with caution.
Posted in Advertising, Corporate Responsibility, E-Media, FDA, Market Access, Marketing, Regulatory, Strategy, healthcare, leadership, patient education | Tagged , , , , , | 1 Comment

Drug Reimbursement and the "New Medicaid"

By Guest Blogger | Published: August 9, 2012
by Tom Norton A lot has been written about the “state option” created by the Supreme Court ruling on HCR, and what it means to American medicine. Sorting out an opinion will, to a degree, depend on whom you read and what you believe. But regardless of where you come out on this issue, there is little [...]
Posted in Guest Blog, Legal, Market Access, R&D, Regulatory, healthcare | Tagged , , , , , , , , | 1 Comment

Public Interest in Private Science: New Pathways to Measuring R&D Success

By William Looney | Published: August 8, 2012
Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question:  are industry R&D priorities in synch with the changing burden of disease?
Posted in FDA, R&D | Tagged , , , | Leave a comment

Forest Labs Hit with Bad Ad Tattle

By Ben Comer | Published: August 7, 2012
Forest Labs has had a tough time with regulators over the last two years. The company’s sales reps can’t seem to stop breaking the law. The latest offense, which generated an Untitled Letter from the Office of Prescription Drug Promotion (OPDP), was brought to light through OPDP’s Bad Ad program, which encourages physicians to report on [...]
Posted in Corporate Responsibility, FDA, Legal, Marketing, Regulatory, Sales, compliance | Tagged , , , , , , , | Leave a comment

Bristol-Myers Squibb's Summertime Blues

By Ben Comer | Published: August 7, 2012
The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar [...]
Posted in Advertising, Biotech, Deals, FDA, Legal, Marketing, R&D, Regulatory, Safety, Sales, Strategy, compliance, pricing | Tagged , , , , , | Leave a comment